Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
about
Resistance to linezolid caused by modifications at its binding site on the ribosomeDevelopment of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus.Structural Basis for Linezolid Binding Site Rearrangement in the Staphylococcus aureus Ribosome.Motualevic acids and analogs: synthesis and antimicrobial structure-activity relationshipsThe chemical biology of new drugs in the development for tuberculosis.Anti-staphylococcal activities of lysostaphin and LytM catalytic domainPharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosisTotal syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptide[Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].Syntheses and biological studies of novel spiropiperazinyl oxazolidinone antibacterial agents using a spirocyclic diene derived acylnitroso Diels-Alder reaction.The genetic environment of the cfr gene and the presence of other mechanisms account for the very high linezolid resistance of Staphylococcus epidermidis isolate 426-3147LIn vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.Cysteine methylation controls radical generation in the Cfr radical AdoMet rRNA methyltransferaseAntibacterial properties and mode of action of a short acyl-lysyl oligomer.Antibacterial oxazolidinones: emerging structure-toxicity relationships.Linezolid, the first oxazolidinone antibacterial agent.The oxazolidinones: past, present, and future.The chemistry of peptidyltransferase center-targeted antibiotics: enzymatic resistance and approaches to countering resistance.Is repositioning of drugs a viable alternative in the treatment of tuberculosis?Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature.Fragment-based inhibitor discovery against β-lactamaseAnticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis.Antibiotic resistance in Staphylococcus aureus. Current status and future prospects.Linezolid: a promising option in the treatment of Gram-positives.Peripheral modifications of [Ψ[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics.Clostridium difficile isolates with high linezolid MICs harbor the multiresistance gene cfrStructure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.3-[2-(1H-1,3-Benzodiazol-2-yl)eth-yl]-1,3-oxazolidin-2-one.(4-Benzyl-2-oxo-1,3-oxazolidin-5-yl)methyl methane-sulfonate.Chemoselective CaO-mediated acylation of alcohols and amines in 2-methyltetrahydrofuran.Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism and Ultrastructure) Induced by Linezolid and Tedizolid at Clinically-relevant Concentrations in cultured Human HL-60 promyelocytes and THP-1 monocytes.In Vitro Activities of LCB 01-0648, a Novel Oxazolidinone, against Gram-Positive Bacteria.Treatment of Tuberculous Meningitis and Its Complications in Adults.
P2860
Q27006772-254FF5D3-7EB1-4EF7-A105-6E78AAB52021Q33529977-D995C2AC-094E-4167-985F-BF990E991F08Q33654525-705ACC82-C9CB-48D3-A61F-BAE582CAA6F8Q33976409-34A8AF9A-F528-46E5-81A9-06F6D9E111C1Q34054325-5E7A01E6-BB91-4CA7-8F2C-C87D8B68B729Q34294373-DCB30D7F-E6CE-43D5-AD79-F22B17166CC8Q35065732-78CDF814-EA9A-4995-AB47-5B107E78309EQ35224649-8754757E-34CA-42BC-9A3D-AD0EB05B49D1Q35619094-50309C5A-6919-4246-AB5A-0DA99D552A96Q35997992-27B0B835-0DDA-4C86-AEF9-8543FA23B51FQ36667049-93A5B520-9F03-4C27-B814-5240BB99F6CEQ36969769-334478A4-6104-4F48-A3DD-97143DE1044AQ36986036-6359C7D6-705E-400E-A781-C6C23D3095F5Q37274674-2F965071-6D59-4227-9D4A-90577E32B7A6Q37747401-5387A2FE-08DD-4619-9AB8-2E70D7F0C789Q37857331-9FA64797-E628-41B4-8FA2-C14FB739601DQ37970719-5B8B203B-2F1B-4B74-96BC-2B26AB9339B0Q37972308-55D61A00-58D4-4BC0-AF8E-55BE65211106Q38053000-3A4453BE-D89C-4AF1-A793-5E84C74C2798Q38106836-CA046330-5F83-42CB-8383-02C38374D4F8Q38196443-ECECA9C3-3E5E-4BB6-B7E0-5F2B39766CAEQ38639453-CB75A003-46F1-400D-B19E-23E9847E9958Q38728885-6FBFC1EA-0DC4-4014-AF04-7050A87CD506Q39044932-21F27364-BD84-42B2-94A4-75B354D941E4Q40192107-3AF8BD72-C9AA-4521-9989-FCA2DA8AF8D9Q41668894-D388B542-4002-41E7-9CC8-BEB0B28200F8Q41862729-55A5A683-8FF3-4B56-88C5-227F58495510Q42067118-C18CC232-E178-4E3E-A561-7674FAC7F29EQ42366496-92B5968A-011A-4B91-9F14-8214FA91532FQ45205391-B45D1A1C-41F9-4A66-B71A-71733294F672Q47269635-8FA075C6-5FA7-406D-B434-0D61FD5CCEDDQ50855186-449FFCEF-E0D2-4157-8D55-01FAF33447B4Q52680275-06C5E5CF-051C-4099-9DD7-A5B54B07907B
P2860
Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Linezolid (ZYVOX), the first m ...... ious gram-positive infections.
@en
Linezolid (ZYVOX), the first m ...... ious gram-positive infections.
@nl
type
label
Linezolid (ZYVOX), the first m ...... ious gram-positive infections.
@en
Linezolid (ZYVOX), the first m ...... ious gram-positive infections.
@nl
prefLabel
Linezolid (ZYVOX), the first m ...... ious gram-positive infections.
@en
Linezolid (ZYVOX), the first m ...... ious gram-positive infections.
@nl
P2093
P356
P1476
Linezolid (ZYVOX), the first m ...... ious gram-positive infections.
@en
P2093
Douglas K Hutchinson
Michael R Barbachyn
Peter R Manninen
Steven J Brickner
P304
P356
10.1021/JM800038G
P407
P577
2008-03-14T00:00:00Z